Illumination devices for uniform delivery of light to the oral cavity for photodynamic therapy

2011 ◽  
Author(s):  
Cristina Canavesi ◽  
William J. Cassarly ◽  
Thomas H. Foster ◽  
Jannick P. Rolland
2010 ◽  
Vol 268 (2) ◽  
pp. 281-288 ◽  
Author(s):  
Baris Karakullukcu ◽  
Kim van Oudenaarde ◽  
Marcel P. Copper ◽  
W. M. C. Klop ◽  
Robert van Veen ◽  
...  

2012 ◽  
Vol 3 (9) ◽  
pp. 2142 ◽  
Author(s):  
Daniel J. Rohrbach ◽  
Nestor Rigual ◽  
Erin Tracy ◽  
Andrew Kowalczewski ◽  
Kenneth L. Keymel ◽  
...  

1996 ◽  
Author(s):  
Eugeny P. Stranadko ◽  
Oleg K. Skobelkin ◽  
Nikolai A. Markichev ◽  
Michail V. Riabov

2010 ◽  
Author(s):  
Cristina Canavesi ◽  
Florian Fournier ◽  
Thomas H. Foster ◽  
Jannick P. Rolland

2020 ◽  
Vol 23 (6) ◽  
pp. 408-413
Author(s):  
Sergey I. Surkichin ◽  
Luidmila S. Holupova

BACKGROUND: Lichen plane (LP) occurs in 0.5%1% of the population. The exact epidemiology of genital LP is unknown. According to various data, LP occurs in 49% of all cases of vulvar lesions. The LP of the oral cavity and the vulva occurs in 1957% of cases. The clinical forms of LP that occur in the anogenital region in women include the erosive, papulosquamous, and less often hypertrophic forms. No distinct guidelines are available for the treatment of vulvar LP. Except for the use of photodynamic therapy (PDT), no randomized controlled trials have been conducted for the treatment of erosive vulvar LP. The research results have shown that PDT can be effective in lichen plane of the oral cavity. AIM: To evaluate the effectiveness of PDT in women with genital LP compared to topical glucocorticosteroids. MATERIALS AND METODS: The study group included 15 patients with a diagnosis of vulvar LP. The patients were divided into two groups depending on the treatment method. Group 1 patients were treated with PDT. Group 2 patients with topical 0.05% betamethasone cream once daily for 1.5 months. RESULTS: Six months after the last procedure, the regression on the genital LP rating scale was 32% in group 1 patients and 25% in group 2 patients. The severity of pain, according to the visual analog scale, was 29% in group 1 and 22% in group 2. As for adverse events, in group 1, four patients experienced a burning sensation and dryness for 23 days after the procedure, and one patient, after two procedures, had blood discharge, which ceased after 1 day. In group 2, five patients complained of burning and dryness during treatment, two patients had acute candidiasis during treatment, and one patient had bacterial vaginosis. CONCLUSION: The use of PDT can reduce the frequency of use of corticosteroid drugs in the genital area and accordingly reduce the frequency of steroid adverse events, such as atrophy and secondary infection.


2021 ◽  
Author(s):  
Juliano Abreu Pacheco ◽  
Kelly Fernanda Molena ◽  
Camila Raíssa Oliveira Gontijo Martins ◽  
Silmara Aparecida Milori Corona ◽  
Maria Cristina Borsatto

Abstract Introduction: In 2019, a viral and respiratory pathology called COVID-19 emerged in Wuhan, China and spread to other continents. Its main symptoms include fever, cough, dyspnea, myalgia, anorexia and respiratory distress in the most severe cases, which can lead to death. Furthermore, manifestations in the oral cavity such as ageusia and dysgeusia, as well as lesions in other regions of the oral cavity, can be observed.Objective: Are Photobiomodulation (PBM) and Antimicrobial Photodynamic Therapy (aPDT) effective to treat oral manifestations of patients infected with SARS-CoV-2?Methodology: It was defined following the PRISMA guidelines (Preferred Report on Systematic Reviews and Meta-Analysis), and registered in the database in the International Prospective Registry of Systematic Reviews (PROSPERO), including articles published between December 2019 to May 2021, Independent reviewers selected studies, qualitatively extracted data, assessed risk of bias using the Joanna Briggs Institute, assessed certainty of evidence through meta-analysis.Results: Of the 5,959 articles found, 32 fit the types of studies, but only 5 of them attended the pre-established criteria. Data corresponding to the articles, protocols used and clinical outcome were extracted, then submitted to qualitative and descriptive analysis. The results show favoring the associated use of PBMT with aPDT (p=0.004), and the isolated use of PBMT with the result of significant “p=0.005” and good confidence interval (7.18, 39.20) in ulcerative lesions, herpetic, aphthous, erythematous, petechiae and necrotic areas.Conclusion: According to the articles included in this review, PBMT and aPDT were effective in the treatment of oral lesions of patients infected with COVID-19 in a short period of time.


2021 ◽  
Vol 11 ◽  
Author(s):  
Arnaud Lambert ◽  
Lotte Nees ◽  
Sandra Nuyts ◽  
Paul Clement ◽  
Jeroen Meulemans ◽  
...  

Background: Head and neck cancer is typically treated with surgery, radiotherapy, chemoradiation, or a combination of these treatments. This study aims to retrospectively analyse oncological outcomes, adverse events and toxicity of treatment with temoporfin-mediated photodynamic therapy at a single tertiary referral center. More specifically, in a selected group of patients with otherwise (functionally) inoperable oral or oropharyngeal head and neck squamous cell carcinoma.Methods: Twenty-six consecutive patients who received photodynamic therapy for oral or oropharyngeal squamous cell carcinoma from January 2002 until July 2019 at the University Hospitals Leuven were included. These were (1) patients with an accessible recurrent or new primary tumor in an extensively treated area of the head and neck, not suitable for standard treatment, or (2) patients that were judged medically unfit to undergo standard treatment modalities.Results: Complete tumor response immediately after PDT was obtained in 76.9% of cases. During follow-up, a proportion of CR patients did recur, to reach recurrence-free rates at six months, one year and two years of 60.6%, 48.5% and 32.3%. Local control at the PDT treated area was 42.3% with a median recurrence free interval time of 9 months. Recurrence-free interval was statistically more favorable for oropharyngeal squamous cell carcinoma (with or without oral cavity extension) in comparison to oral cavity squamous cell carcinoma alone (p < 0.001). During a median follow-up period of 27 months, we report new tumor activity in 80.8% of patients. Median overall and disease-specific survival time was 31 and 34 months, respectively. Most reported adverse events were pain after treatment and facial edema. At the end of follow-up, swallowing and upper airway functionality were preserved in 76.9 and 95.7% of patients, respectively.Conclusion: Photodynamic therapy is a valuable treatment option in highly selected patients with oral and/or oropharyngeal (functionally) inoperable head and neck squamous cell carcinoma. Treatment with this alternative modality can induce durable local control in an important fraction of treated patients, with an acceptable toxicity profile.


Sign in / Sign up

Export Citation Format

Share Document